

GENEKOR MEDICAL S.A. All rights reserved.

# **Genekor Medical S.A.**


info@genekor.com | www.genekor.com





# MyTheragene

Personalized pharmacotherapy  
based on human DNA.



**Genekor**

Committed to Biotechnological Innovation

# MyTheragene®

**MyTheragene®** test analyzes the metabolic path of each patient for over 500 drugs related to simple and everyday medical problems, such as headaches, high blood pressure, etc. but also with difficult to manage diseases and disorders such as schizophrenia, depression, neurogenic disorders, etc.

**Pharmacogenomics** is a rapidly evolving branch of clinical pharmacology that deals with the research and study of genetically determined irregularities that affect:

- metabolism (pharmacokinetics)
- the action (pharmacodynamics) of drugs in humans.

The proteins and enzymes that regulate each individual's response to drugs often show functional differences due to genetic background.

## FDA on Pharmacogenomics

**Pharmacogenomics** can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose.

**Drug labeling** may contain information on genomic biomarkers and can describe:

- Drug exposure and clinical response variability
- Risk for adverse events
- Genotype-specific dosing
- Mechanisms of drug action
- Polymorphic drug target and disposition genes
- Trial design features

### **Pharmacogenomic Biomarkers in Drug Labeling (FDA)**

Over 500 entries that relate specific drugs with pharmacogenomic biomarkers have been posted and are constantly updated in FDA's official website.

**MyTheragene®** is an innovative multi-gene test, with high sensitivity and specificity, which is based on pharmacogenomic science and analyzes 40 genes related to the metabolic pathway for over 500 drugs.

## Who Should Be Tested

It is suitable for everyone who is on or is about to go on medication, but it is essential for the following groups of patients:

- » Patients with complicated drug prescriptions and multiple diseases
- » Patients who show little or no response to current treatment
- » Patients who experience side effects from current treatment
- » Patients with chronic diseases
- » Patients with rare or severe disorders
- » Patients with severe allergies to drugs

## Why Mytheragene®

The **MyTheragene®** pharmacogenomic examination helps the physician to select the most appropriate drug and dosage for the best patient response to treatment.

### ***In this way we achieve:***

- The highest possible efficiency of treatment
- Reduction of cost & healing time and / or adjustment for the patient
- Easier and more reliable choice among drugs per patient for the Physician

## MyTheragene® Gene Panel

ABCB1	ABCG2	ADRA2A	ANK1	APOE	COMT	CYP1A2	CYP2B6	CYP2C19	CYP2C8
CYP2C9	CYP2D6	CYP3A4	CYP3A5	DBH	DPYD	DRD1	DRD4	F2	F5
FLOT1	GABRA6	GABRP	GRIK4	HCP5	HLA-A	HTR2A	HTR2C	ITGB3	KIF6
MTHFR	OPRD1	OPRK 1	OPRM1	SLCO181	TPMT	UGT1A1	UGT2B15	UGT2B7	VKORC1

**Sample Requirement: 2 vials of peripheral blood (EDTA) or buccal Swab**

**TAT: 10 Working Days**

**The test can significantly improve the drug prescription procedure in the following Medical Fields:**

- Cardiology
- Neurology
- Psychiatry
- Oncology
- Endocrinology
- Gynecology
- Gastroenterology
- Immunology
- Dermatology
- Nephrology
- Ophthalmology
- Urology
- Otolaryngology
- Rheumatology
- Hematology

**Methodology → NGS Ion Gene S5 Prime System**